electroCore (ECOR) Scheduled to Post Earnings on Wednesday

electroCore (NASDAQ:ECOR) is scheduled to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect electroCore to post earnings of ($0.50) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

electroCore (NASDAQ:ECOR) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06). The company had revenue of $5.19 million for the quarter, compared to analysts’ expectations of $5.23 million. electroCore had a negative net margin of 117.49% and a negative return on equity of 201.47%. During the same period last year, the company posted ($1.22) EPS. On average, analysts expect electroCore to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

electroCore Trading Up 4.1 %

Shares of NASDAQ:ECOR traded up $0.26 during trading on Monday, reaching $6.59. 2,578 shares of the company traded hands, compared to its average volume of 12,443. The firm has a market capitalization of $39.54 million, a price-to-earnings ratio of -1.78 and a beta of 0.91. electroCore has a 52-week low of $3.83 and a 52-week high of $8.08. The business’s fifty day moving average is $6.20 and its 200-day moving average is $6.22.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating on shares of electroCore in a research note on Thursday, March 14th.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.